Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-862-4 | CAS number: 42797-18-2
Endpoint summary
Administrative data
Description of key information
The oral and dermal LD50 values were above the highest tested dose in acute studies conducted with 2-(4Phenylbenzoyl)benzoic acid.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 500 mg/kg bw
- Quality of whole database:
- The information requirements for a PPORD dossier is sufficiently met with the available data.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- The information requirements for a PPORD dossier is sufficiently met with the available data.
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The information requirements for a PPORD dossier is sufficiently met with the available data.
Additional information
The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2500mg/kg body weight.
The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight.
Justification for selection of acute toxicity – oral endpoint
This is the only available study, which is conducted according to the OECD guidelines and GLP compliant.
Justification for selection of acute toxicity – inhalation endpoint
no study selected
Justification for selection of acute toxicity – dermal endpoint
This is the only available study, which is conducted according to the OECD guidelines and GLP compliant.
Justification for classification or non-classification
Based on the LD50 values obtained in acute oral and dermal toxicity studies conducted with 2-(4Phenylbenzoyl)benzoic acid, 2-(4Phenylbenzoyl)benzoic acid is not considered to require classification for acute effects according to EC (67/548/EEC) and CLP (EC 1272/2008) criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
